B. Riley analyst Mayank Mamtani lowered the firm’s price target on TG Therapeutics (TGTX) to $24 from $32 and keeps a Buy rating on the shares. Roche’s (RHHBY) Q3 report confirms flattening of recent U.S. Ocrevus’ prescription volume trends and Symphony institutional prescription sales data drives the firm to make “conservative downward revisions,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
- TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
- New Sales Data Hits TG Therapeutics (NASDAQ:TGTX) Hard
